Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Erythropoietin (EPO) Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The erythropoietin (epo) market has seen substantial growth in recent times. Its value is forecast to expand from $19.25 billion in 2025 to $21.46 billion by 2026, achieving a compound annual growth rate (CAGR) of 11.5%. Key drivers for this historical expansion include the increasing prevalence of anemia, a growing incidence of chronic kidney disease, the established clinical effectiveness of epo therapy, progress in recombinant biologic manufacturing, and the expanded application of epo in the management of cancer-related anemia.
The erythropoietin (epo) market is projected to experience significant growth in the upcoming years. It is anticipated to expand to $35.04 billion by 2030, achieving a compound annual growth rate (CAGR) of 13.0%. This growth during the forecast period can be attributed to an increase in biosimilar approvals, a growing elderly demographic, a rising global volume of dialysis patients, innovations in sustained-release epo drugs, and improved access to biologic therapies in emerging economies. Noteworthy trends for the forecast period include the expanded use of erythropoietin in chronic kidney disease, increasing adoption of biosimilar erythropoietin therapies, growing demand for long-acting epo formulations, more frequent use of epo in oncology supportive care, and stricter regulatory oversight concerning epo safety and dosing.
Get A Free Sample Report With In-Depth Market Insights:
Erythropoietin (EPO) Market Growth Factors: What’s Supporting Expansion?
The erythropoietin market is expected to experience increased demand in the upcoming years, driven by the growing occurrence of chronic kidney diseases. Erythropoietin is administered in an increasing number of chronic kidney disease cases because it helps produce red blood cells to boost immunity. For example, data from 2023, as per the Centers for Disease Control, a US-based federal agency, estimates that roughly 14% of U.S. adults, which translates to about 35.5 million people, are affected by chronic kidney disease (CKD). Consequently, the escalating incidence of chronic kidney diseases directly raises the demand for erythropoietin, thus propelling the market’s revenues.
Erythropoietin (EPO) Market Breakdown By Product Type And Application
The erythropoietin (epo) market covered in this report is segmented –
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologist, Biosimilar
3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications
Subsegments:
1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars
2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars
3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars
4) By Other Products: Peginesatide, Novel EPO Products
Erythropoietin (EPO) Market Industry Trends: What’s Reshaping Demand?
Leading companies within the erythropoietin market are concentrating on introducing oral medications, which serve as more convenient options than conventional injectable therapies. This initiative seeks to enhance patient comfort, adherence, and treatment flexibility, particularly for individuals managing chronic ailments such as anemia associated with chronic kidney disease (CKD). For example, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology company, released Jesduvroq (daprodustat) tablets. This oral medicine works to elevate erythropoietin levels, thereby aiding in the management of anemia in CKD patients by sustaining hemoglobin levels within a specified range. The core purpose of Jesduvroq is to present a more accessible alternative to injectable treatments, thereby improving patient comfort, compliance, and treatment flexibility for dialysis patients.
Erythropoietin (EPO) Market Company Landscape And Competitive Strategy
Major companies operating in the erythropoietin (epo) market are Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.
View The Full Erythropoietin (EPO) Market Report:
Erythropoietin (EPO) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the erythropoietin (EPO) market in 2025. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
